Physician profile
Walter R Byrd
NPI 1427023985
$299,344.94
in general payments reported to CMS, 2019-2025
11 companies · $54K in 2025
The $54K reported for 2025 was more than what 98% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172K · 2020: $11K · 2021: $90.51 · 2022: $14K · 2023: $22K · 2024: $26K · 2025: $54K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62K · Consulting Fee: $29K · Travel and Lodging: $7,740 · Food and Beverage: $3,840 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,453.00 |
| Consulting Fee | $28,525.50 |
| Travel and Lodging | $7,740.33 |
| Food and Beverage | $3,840.31 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $145,208.43 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Neurocrine Biosciences, INC. | $86,913.11 | 2019-2025 | Ingrezza |
| E.R. Squibb & Sons, L.L.C. | $27,790.74 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $18,055.42 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $12,412.39 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $7,405.77 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $655.08 | 2021-2025 | Caplyta |
| Abbvie INC. | $329.38 | 2025 | |
| Alkermes, INC. | $298.30 | 2022-2024 | Lybalvi |
| Axsome Therapeutics, INC. | $245.53 | 2023-2025 | Auvelity |
| Tris Pharma INC | $30.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Walter Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.